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The initial steps of Venezuelan equine encephalitis virus (VEE) spread from inoculation in the skin to the
draining lymph node have been characterized. By using green fluorescent protein and immunocytochemistry,
dendritic cells in the draining lymph node were determined to be the primary target of VEE infection in the first
48 h following inoculation. VEE viral replicon particles, which can undergo only one round of infection,
identified Langerhans cells to be the initial set of cells infected by VEE directly following inoculation. These
cells are resident dendritic cells in the skin, which migrate to the draining lymph node following activation. A
point mutation in the E2 glycoprotein gene of VEE that renders the virus avirulent and compromises its ability
to spread beyond the draining lymph blocked the appearance of virally infected dendritic cells in the lymph
node in vivo. A second-site suppressor mutation that restores viral spread to lymphoid tissues and partially
restore virulence likewise restored the ability of VEE to infect dendritic cells in vivo.
Venezuelan equine encephalitis virus (VEE) is a positive-
sense, single-stranded RNA Alphavirus belonging to the family
Togaviridae. Epizootic strains of VEE cause significant disease
in horses and humans, as evidenced by the 1995 to 1996
epizootic in Venezuela and Columbia, during which an esti-
mated 60,000 humans were infected following outbreaks in
surrounding horse populations (35). VEE is transmitted by
mosquitoes, typically of the subgenus Culex, during the course
of a blood meal. Infection by VEE causes a biphasic illness in
equines. The first phase is characterized by fever and viral
replication in lymphoid tissues, with a high serum viremia (14,
19). In the second phase, in spite of immune system-mediated
clearance from peripheral tissues, virus invades the central
nervous system and leads to an often lethal encephalitis. In-
fection in humans results in much milder disease than that seen
in equines and ranges from asymptomatic to flu-like symptoms
and fever, with approximately 0.1 to 0.7% of cases resulting in
encephalitis, most commonly in children and the elderly (18).
Infection in rodent models closely parallels the encephalitic
disease seen in horses (14, 23). Following a subcutaneous (s.c.)
inoculation in the rear footpad of a mouse, replicating virus is
first observed in the draining lymph node within 4 h postin-
oculation (p.i.). This precedes replication at the site of inocu-
lation in the footpad by 6 to 8 h, suggesting that the primary
amplification occurs at the first lymphoid tissue encountered
and not at the site of inoculation (J. F. Aronson, N. L. Davis,
F. B. Grieder, P. C. Charles, T. A. Knott, K. W. Brown, and
R. E. Johnston, unpublished data). Virus titers of 106 to 107
PFU/g of tissue are observed in the draining node as early as
6 h p.i. (2). By 12 to 24 h p.i., high titers are observed in other
lymphoid tissues and serum, with lower titers being found in
several nonlymphoid tissues. By 48 to 72 h p.i., the titers begin
to decline, with necrosis in infected tissues. Complete clear-
ance from the periphery occurs by 72 to 96 h p.i. However, at
this point virus has already spread from the blood to the cen-
tral nervous system via the olfactory and trigeminal nerves,
terminating in a fatal encephalitis 7 to 10 days p.i. (6).
Although lymphoid tissues represent a significant site of
viral replication in the early stages of VEE pathogenesis (14,
23, 34; Aronson et al., unpublished), specific cell targets for
viral replication had not been identified. VEE expression vec-
tors (10, 27) encoding either the green fluorescent protein
(GFP) or influenza virus hemagglutinin (HA) were used in
conjunction with immunocytochemistry to demonstrate that
VEE primarily targets dendritic cells (DC) in the lymph nodes.
The use of VEE viral replicon particles (VRP), which can
undergo only one round of infection, showed that VEE initially
infects Langerhans cells, the resident DC in the skin which
migrate to the draining lymph node following activation. A
point mutation in the E2 glycoprotein gene of VEE that ren-
ders the virus avirulent and compromises its ability to spread
beyond the draining lymph node (11, 18) blocked the appear-
ance of virally infected DC in the lymph node in vivo. A
second-site suppressor mutation that restores viral spread to
lymphoid tissues and partially restores virulence (Aronson et
al., unpublished; K. A. Bernard, personal communication) like-
wise restored the ability of VEE to infect DC in vivo.
MATERIALS AND METHODS
Virus and mice. This study used viral particles derived directly from transfec-
tion of full-length or partial RNA transcripts of VEE cDNA clones into baby
hamster kidney (BHK) cells. These clones include pV3000, derived from the
Trinidad donkey strain of VEE (11, 12), and two mutated clones, pV3010 (11,
18) and pV3533 (Aronson et al., unpublished). The infectious virus derived from
these full-length clones are designated V3000, V3010, and V3533, respectively.
V3010 is isogenic with V3000 except at E2 76 (Glu 3 Lys). V3533 is a second-
site revertant of V3010 that was generated by the insertion of a suppressor
mutation at E2 116 (Lys 3 Glu) into the V3010 background. The E2 116
suppressor mutation was identified as a constituent mutation in a V3010 rever-
tant isolated from the serum of a V3010-infected mouse. The replication of
V3533 in mice appears identical to that of the in vivo-isolated revertant.
Two types of VEE expression vectors derived from V3000 were used in these
studies (Fig. 1): a double-promoter vector (dpV3000) (10) and a replicon vector
(27). dpV3000 contains a second copy of the 26S subgenomic promoter inserted
near the 39 end of the V3000 genome. dpV3000-GFP was generated by inserting
a copy of a mutated form of GFP (mut2GFP) (7) downstream of the second 26S
promoter. This vector produces propagation-competent virus particles which
express GFP following infection and which can spread from cell to cell. In
contrast, the replicon expression vectors have had the structural genes directly
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replaced by a heterologous gene (10, 27) and were used to produce propagation-
defective viral particles, which are limited to one round of infection.
Two replicon vectors, one expressing influenza virus HA (pHA-VRP) (27) and
one expressing mut2GFP (pGFP-VRP), were used in these studies. pGFP-VRP
was generated by cloning mut2GFP directly behind the 26S promoter in the place
of the structural genes. Infectious VRP were produced from these vectors by
coelectroporation into BHK cells of RNA transcripts from the pGFP-VRP or
pHA-VRP, respectively, with two VEE helper vectors expressing VEE capsid
and glycoprotein genes (Fig. 1c). Both helper vectors lack the viral packaging
signal, which results in only the pGFP-VRP or pHA-VRP genome being pack-
aged in VRP. GFP-VRP-3000 and HA-VRP-3000 were produced by electropo-
ration with helpers expressing the wild-type (V3000) glycoproteins, whereas the
mutated VRPs, GFP-VRP-3010 and GFP-VRP-3533, were packaged by using
glycoprotein helpers containing the V3010 and V3533 mutations, respectively.
While VRP are fully infectious, they can undergo only one round of infection and
were used to study the initial events of infection in vivo without the production
and spread of viral progeny. The titer was determined on BHK cells as infectious
units (IU) by either immunofluorescence or immunocytochemistry.
Female CD-1 or C57BL/6 mice, 7 to 8 weeks old (Charles River Laboratories,
Wilmington, Mass., and Jackson Laboratory, Bar Harbor, Maine, respectively)
were inoculated s.c. in the footpad with 103 to 104 PFU of virus or IU of VRP.
GFP detection and immunocytochemistry. At 7 to 48 h p.i., mice were per-
fused with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), and
the draining popliteal lymph nodes were removed. For leg sections, whole legs
were decalcified in 8% EDTA–4% PFA for 6 weeks before the sectioning was
performed. GFP-positive cells were visualized by fluorescence microscopy of
fixed frozen sections by using a fluorescein isothiocyanate filter set. The following
antibodies (Abs) were used for immunostaining: rabbit anti-VEE (kind gift of J.
Smith, Ft. Detrick, Fredrick, Md.), anti-DEC 205 (NLDC145; American Type
Culture Collection) and anti-CD11C (N418; American Type Culture Collection)
for DC, anti-CR-1 (PharMingen) and anti-FcgIII/IIR (PharMingen) for follicu-
lar DC; anti-CD11B (MAC-1) for macrophages, anti-MHC II IAd1b (clone
25.9.175; both kindly provided by S. Virgin, Washington University, St. Louis,
Mo.), anti-CD45R (B220; PharMingen) for B cells, and anti-CD5 specific for T
cells and Ly1 B cells (PharMingen). Rabbit anti-flu (H1N1; kindly provided by R.
Webster, St. Jude’s Children Hospital, Memphis) was used to detect influenza
virus HA. Species-matched normal sera or isotype-matched monoclonal Ab
(MAb) (PharMingen) was used in all immunostaining steps as the negative
control primary Ab. To optimize DEC 205 reactivity, fixed frozen sections were
steamed for 25 min (or, in the case of tissues with GFP, warmed to 55°C for 1 h)
in 10 mM citrate (pH 6.0). Immunostaining patterns obtained by epitope re-
trieval methods were confirmed by using fresh tissue sections fixed in acetone (10
min). Sections were blocked in 10% normal serum (with 0.1% Tween 20 in PBS
for DEC 205) for 1 h, washed in PBS, and incubated with the primary Ab
overnight at 4°C. Sections were incubated with a secondary Ab with the appro-
priate fluorochrome (CY2, CY3, or Texas Red) either directly conjugated to the
Ab or through an avidin-biotin bridge (Jackson ImmunoResearch Laboratories).
Isolation of VEE-infected cells. Mice were inoculated in all four footpads with
103 PFU of dpV3000-GFP, and 2 h later the popliteal, lateral iliac, accessory
axial, and proper axial lymph nodes were removed and minced into 1-mm2 pieces
on ice in complete medium (RPMI-C: RPMI 1640, 10% fetal bovine serum FBS,
25 mM HEPES [pH 7.2], 100 U of penicillin per ml, 100 mg of streptomycin per
ml, 0.25 mg of amphotericin B per ml, 2 mM L-Gln, 50 mM 2-mercaptoethanol,
1 mM sodium pyruvate, 0.1 mM nonessential amino acids). Tissue fragments
were digested with collagenase (Sigma; type IA, 100 mg/ml) and DNase (Sigma;
30 U/ml) for 90 min at 37°C. At 30-min intervals during the digestion, the
fragments were gently pipetted and the suspension cells were removed to ice,
with fresh enzymes being added to the remaining fragments. The final cell
suspension was passed through a 70-mm nylon cell sieve (Falcon) and washed
twice. DC and macrophages were separated from lymphocytes by density cen-
trifugation of a suspension of 0.5 3 106 to 1 3 106 cells/ml over a 14.5%
Nycodenz (GIBCO BRL) cushion at 600 3 g for 20 min at 27°C. Low-density
cells at the interphase (macrophages and DC) were separated from pelletted
lymphocytes, and both fractions were cultured in RPMI-C overnight (14 to 16 h)
at 37°C. DC were removed from the low-density cell culture by rigorous pipet-
ting, leaving the strongly adherent macrophages. The dendritic, macrophage, and
lymphocyte fractions were fixed in 4% PFA, and the number of GFP-positive
cells in each fraction was counted by fluorescence microscopy. The purity of the
DC and lymphocyte fractions was checked by immunofluorescence with DEC
205-, CD11B-, CD11C-, B220-, and CD5-specific Ab. Macrophages, T cells, and
B cells represented 0.3, 1.0, and 5.8% of the DC fraction, respectively. Likewise,
DC and macrophages represented 0.6 and 0.9%, respectively, of the lymphocyte
fraction.
Kinetics of migration of VEE-infected cells. To determine the movement of
VEE-infected cells from the site of inoculation to the draining lymph node, mice
were inoculated s.c. with 103 IU of GFP-VRP-3000 in the rear footpad. At the
FIG. 1. Genetic maps of V3000 clones and vectors. Diagrams of the parental virus, V3000, depicting positions of the genomic promoter (G), the sub-genomic 26S
promoter (26S) and the nonstructural (nsP1-nsP4), capsid, and glycoprotein genes (E1 to E3) (a), the double promoter expression vector, dpV3000-GFP (b), and the
replicon expression vector system with pGFP-VRP, capsid, and glycoprotein helpers (c). In the expression replicon, the structural protein genes were deleted and
replaced with the mut2GFP gene immediately downstream of the 26S promoter. The VEE capsid gene and the glycoprotein genes were supplied on separate helper
RNAs in which the 59 and 39 ends of the VEE genome were retained but from which most of the nonstructural gene region, including the encapsidation signal, was
deleted (7). When coelectroporated into the same cell, these three RNAs supply all the required VEE functions resulting in the assembly and release of infectious VRP
encoding GFP into the culture media.
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times specified, two mice were sacrificed by cervical dislocation, the femoral
arteries were severed, and the footpad and draining lymph nodes were surgically
removed. Tissue explants were cultured at 37°C in RPMI-C for a total of 12 h (in
vivo plus ex vivo) prior to fixation in 4% PFA. Tissues were serially sectioned,
and the total number of GFP-positive cells in each tissue was determined by
fluorescence microscopy.
RESULTS
VEE infects DC in the draining lymph node. The dpV3000-
GFP vector encodes all virus genes in addition to GFP and
allows viral spread from cell to cell over time to be studied by
FIG. 2. VEE infects DC in the draining lymph node. Sections of the draining popliteal lymph node 12 h following s.c. inoculation in the rear footpad either with
103 PFU of dpV3000-GFP (a to c), showing the distribution and morphology of GFP-positive cells in the cortex of the draining popliteal lymph node (a and b)
(magnification, 3100 and 3400, respectively) and around B-cell follicles immunostained with the B-cell-specific Mab, B220 (c) (magnification, 3200), or with 103 PFU
of V3000 (d to f), showing double immunostaining with VEE-specific Ab (CY2; green) and the DC-specific Ab, DEC 205, (Texas Red; red) visualized by using either
Texas Red filters (d), fluorescein isothiocyanate filters (e), or triple-pass filters allowing simultaneous visualization of CY2 and Texas Red (f; magnification, 3400).
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identification of cells expressing GFP. Draining lymph nodes
were harvested from mice at 12, 24, and 48 h after inoculation
with dpV3000-GFP. At 12 h p.i., GFP-positive cells with mor-
phology similar to DC were observed in the paracortex of the
lymph node (Fig. 2a and b). No GFP signal was detected in
tissues from mice inoculated with dpV3000-GFP having the
GFP gene cloned in the antisense orientation. Immunostaining
with the B-cell-specific Ab, B220, revealed that the GFP-pos-
itive cells were restricted to the interfollicular regions of the
paracortex and in close proximity to B-cell follicles (Fig. 2c).
By 24 and 48 h p.i., GFP-positive cells were seen deeper in the
cortex. As at 12 h p.i., only a few positive cells were seen in the
medulla. No apparent change in the cell type infected was
observed at these later time points. At all time points, occa-
sional positive cells were observed in the lumen of the medul-
lary cords and possibly represented emigration of infected cells
into the lymphatics.
The cytoplasmic expression of GFP made it difficult to con-
firm the identity of infected cells by using surface markers.
Therefore, mice were inoculated with the parental virus,
V3000, and lymph node sections were doubly immunostained
with VEE-specific Ab in combination with lymphocyte or DC-
specific Ab. A similar pattern of VEE positive cells in the
paracortex was observed with V3000 as was initially observed
with the dpV3000-GFP vector. Double immunostaining re-
vealed that cells positive for VEE also were positive for the
DC-specific marker, DEC 205 (Figure 2d to f). VEE-positive
cells, however, were negative for the B-cell marker, B220 (data
not shown), consistent with the localization of GFP-positive
cells outside of B-cell follicles. VEE-positive cells also were
negative for CD5, a pan-T-cell and Ly1 B-cell marker (data not
shown). Immunostaining with serum and isotype-matched con-
trol Ab confirmed the specificity of this staining (data not
shown). Similar results were found when tissue sections from
mice inoculated with dpV3000-GFP were immunostained with
these Ab. The status of CD11C reactivity of infected cells
could not be determined under the fixation conditions required
for inactivating propagative virus. These results indicate that
DEC 205-positive DC in the paracortex represent a major cell
target in the draining lymph node for infection by VEE.
GFP-positive cells cofractionate with the DC population
from lymph nodes of mice infected with VEE. To confirm the
targeting of VEE to DC, lymph nodes were removed from
mice soon after inoculation with dpV3000-GFP. Tissue ho-
mogenates were fractionated into lymphocytes, macrophages,
and DC by density centrifugation, cultured overnight, and
scored for the number of GFP-positive cells (Table 1). The DC
fraction consistently contained 2 orders of magnitude more
GFP-positive cells than did the lymphocyte fraction. No posi-
tive cells were observed in the macrophage population in one
experiment, and the four positive cells observed in the second
experiment were loosely adherent, most probably representing
DC that had not been removed from the dish. These results are
consistent with the immunocytochemical observations indicat-
ing that DC represent a major target for infection by VEE.
Langerhans cells are the first cells infected by VEE follow-
ing s.c. inoculation. VRP are propagation-defective viral par-
ticles and can undergo only one round of infection. Therefore,
VRP-infected cells necessarily represent the population of
cells first infected by the virus. VRP expressing either GFP or
HA (Fig. 1c) were used to identify the initial set of cells which
are infected by the virus following an s.c. injection in the
footpad. Mice were inoculated with a low dose (103 IU) of
GFP-VRP-3000 s.c. in the rear footpad, and serial sections of
either the whole leg or the draining popliteal lymph node were
examined. Examination of whole-leg serial sections at 12 and
24 h p.i. revealed that GFP-positive cells were found exclu-
sively in the draining popliteal lymph node in the subcapsular
region of the cortex (Fig. 3a and b). No signal was observed in
any other tissues, including the footpad. Identical results were
found when mice, inoculated with dpV3000-GFP, were sacri-
ficed at 7.5 h p.i., the earliest time at which GFP could be
detected (data not shown). The large size of the GFP-positive
cells (cell bodies 20 to 30 mm in diameter) and their morphol-
ogy with extensive processes that could be tracked through
three to four serial 30-mm-thick sections were similar to those
of Langerhans cells found in the skin. These GFP-positive cells
only rarely were observed deeper in the node, even at 24 to
48 h p.i. and persisted up to 5 days following inoculation
without showing significant changes in morphology. The phe-
notype of these cells was confirmed by double immunostaining
in lymph nodes from mice inoculated with VRP expressing HA
as a cell surface marker (HA-VRP-3000). Cells that were pos-
itive for HA (Fig. 3c and e) were weakly positive for DEC 205
and for major histocompatibility complex (MHC) class II (Fig.
3d and f) but were negative for lymphocyte and macrophage
markers (CD5 and CD11B) as well as the DC marker, CD11C
(data not shown). A 10-fold-higher dose of VRP (104 IU)
resulted in a small proportion of HA-positive cells in the para-
cortex that were negative for CD5 and B220 but were positive
for CD11C and CD11B, indicating that at higher doses other
subsets of antigen-presenting cells, including macrophages,
could be infected.
To determine the kinetics of migration of infected cells
and/or free virus from the site of inoculation to the draining
lymph node, footpads and draining popliteal lymph nodes from
mice inoculated with 103 IU of GFP-VRP-3000 were surgically
removed at time points between 7 min and 3 h p.i. and placed
in organ culture to allow the expression of GFP. Tissues were
cultured for a total time of 12 h (in vivo plus in vitro) and fixed,
and the total number of GFP-positive cells in serial sections
was determined (Fig. 4). No GFP-positive cells were recovered
in the media or adherent to the plastic in any of the cultures.
The number of GFP-positive cells in the footpad declined to 0
by 30 min after inoculation, suggesting a rapid emigration of
infected cells from the site of inoculation. Likewise, a signifi-
cant number of GFP-positive cells were observed in the lymph
node at 30 min and reached a plateau between 1 and 2 h. This
time course is consistent with VEE infection of Langerhans
cells at the site of inoculation and subsequent movement of
these cells to the draining lymph node. It appears that this is an
efficient process, since approximately 45% of the inoculated
VRP could be recovered as GFP-positive cells in the lymph
node.
TABLE 1. VEE-infected cells cofractionate with DC
from the lymph node
Expt Cell fraction No. of GFP-positivecells per 107 cells
Total no. of GFP-positive
cells countedc
1 DC 660b 178
Lymphocytes 0.4a 1
Macrophages 0b 0
2 DC 556b 139
Lymphocytes 4a 16
Macrophages 4b 4
a Number of GFP-positive cells counted per 107 lymphocytes plated.
b Number of GFP-positive cells counted per 107 low-density cells plated.
c Total number of cells counted per fraction.
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A single mutation in the VEE E2 glycoprotein gene prevents
infection of DC in the lymph node. A single mutation intro-
duced into the E2 glycoprotein gene of V3000 to generate the
V3010 mutant severely affects both the virulence of the virus
and the ability of the virus to spread beyond the draining lymph
node (11, 18). VRP were packaged in V3010 structural pro-
teins to determine the effect of this mutation on the targeting
of Langerhans cells. Examination of serial sections through
FIG. 3. Langerhans cells are the first cells infected following inoculation. (a and b) A leg section showing the draining popliteal lymph node 12 h following s.c.
inoculation in the rear footpad with 103 IU of GFP-VRP-V3000 (magnification, 3100 and 3400, respectively). (c to f) Draining lymph node sections from mice 8 h
after being infected with 103 IU of HA-VRP-3000 were doubly immunostained with Ab specific for either influenza virus (c and e), DC (d; DEC 205), or MHC class
II (f), and 0.5-mm-thick sections were analyzed by confocal microscopy (magnification, 3600).
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entire draining lymph nodes demonstrated that this mutation
effectively prevents the appearance of GFP-positive Langer-
hans cells in the draining lymph node. Occasionally, small,
irregular GFP-positive cells were observed deep in the medulla
(Fig. 5a). These cells also were found at low frequencies in
lymph nodes from mice inoculated with V3000. No GFP-pos-
itive cells were observed in other tissues of the lower leg,
including the site of inoculation in the footpad.
A second-site suppressor mutation restores the ability of
VEE to infect DC in vivo. The introduction of a second-site
suppressor mutation into the V3010 E2 glycoprotein gene
(clone V3533), originally isolated as an in vivo reversion, re-
stores the ability of the virus to spread and replicate in lym-
phoid tissues beyond the draining lymph node and partially
restores viral virulence (Aronson et al., unpublished; Bernard,
personal communication). We tested the effect of this second
mutation on cell targeting in vivo by inoculating mice with
VRP packaged in V3533 glycoproteins. At a dose of 103 IU,
GFP-VRP-V3533 infected cells with a DC-like morphology
located within B-cell follicles (Fig. 5b). These cells were posi-
tive for FcgIII/IIR (Fig. 5d) and CR-1 (Fig. 5f), consistent with
markers of follicular DC (22), but were negative for DEC 205,
CD11B, CD11C, and lymphocyte markers. At a higher dose of
104 IU, GFP-VRP-3533 infected cells that were positive for
DEC 205, CD11B, and CD11C (data not shown), similar to
VRP-3000 at 104 IU. These results demonstrate that at lower
doses, the V3533 revertant has acquired the ability to infect a
new subset of DC, but at higher doses, it infects a cell popu-
lation comparable to that infected by the wild-type virus.
DISCUSSION
The initial events in the course of viral infection often de-
termine the outcome and severity of viral disease. We have
characterized the initial steps of VEE spread and pathogenesis
from the s.c. site of inoculation to the draining lymph node.
Through the use of propagation-defective VEE vectors, we
have demonstrated that Langerhans cells, DC of the skin, were
the first cells infected via this route of inoculation. Identical
results were found when mice were inoculated with propaga-
tion-competent virus expressing GFP and were sacrificed at the
earliest time when GFP could be detected. GFP expression in
these cells unambiguously confirms a productive viral infection
as opposed to antigen trapped on cell surfaces. While it is
possible that DC have taken up GFP via phagocytosis of other
infected cell types, both the uniform distribution of GFP in the
cytoplasm and the limited phagocytic characteristics of lymph
node DC argue against this.
At later time points, virus spreads to DC that are strongly
positive for DEC 205 in the paracortex of the draining lymph
node. DEC 205 is typically associated with interdigitating DC,
a subset of DC which is associated with the T-cell-rich regions
of the deep cortex of lymph nodes (29). The presence of virally
infected cells that are DEC 205 positive in the subcortical
region between B-cell follicles may be a direct consequence of
VEE infection or may represent a distinct subset of DC which
share this marker with interdigitating DC. The cofractionation
of GFP-positive cells in the DC fraction of lymph nodes further
indicates that DC, as opposed to lymphocytes and macro-
phages, represent the major target of infection in these tissues.
The targeting of VEE to both Langerhans cells and DC is
consistent with data indicating that Langerhans cells differen-
tiate into DC when they migrate from the skin to the lymph
node. Langerhans cells are the resident DC of the skin, where
they act as scavengers or sentinels for foreign antigens (1, 31,
33). These cells are nonmobile and express low levels of MHC
class II and DEC 205. Upon activation by antigen uptake or by
cytokines such as tumor necrosis factor alpha, they differenti-
ate into mobile “veiled cells” and migrate through the lymph to
the draining lymph node. In the lymph node, they further
differentiate into potent antigen-presenting cells which express
high levels of MHC class II and DEC 205 (1, 8, 9, 29, 31, 33).
Langerhans cells infected with VRP appeared to have retained
the characteristics of skin Langerhans cells in the lymph node
without further maturation, even over the 5-day period during
which they can be detected in the node. Alphaviruses inhibit
FIG. 4. Kinetics of the movement of VEE-infected cells. Numbers of GFP-positive cells in the footpad (hatched) and in the draining popliteal lymph node (solid)
were determined immediately following s.c. inoculation in the rear footpad with 103 IU of GFP-VRP-3000. At the times specified, tissues were surgically removed and
cultured as tissue explants at 37°C for a total of 12 h (in vivo plus ex vivo). Tissues were serially sectioned, and the total number of GFP-positive cells in each tissue
was determined by fluorescent microscopy. Each time point represents the averages of two paired footpads and draining lymph nodes.
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host protein synthesis in cultured cells 4 to 6 h after infection
(30). It is possible that VRP infection of Langerhans cells
perturbed cellular protein synthesis to the extent that the mat-
uration of these cells in the lymph node was halted at an
intermediate differentiation state. If this is the case, VEE may
provide a valuable tool in studying Langerhans cell differenti-
ation in vivo and in vitro.
Although a number of viruses are able to infect DC in vitro,
a limited number of organisms have actually been demon-
strated to infect DC in vivo. These include human immunode-
ficiency virus (13, 28), lymphocytic choriomeningitis virus
(LCMV) (3), African swine fever virus (16), adenovirus (15),
murine retrovirus SL3-3 (32), and the protozoan parasite
Leishmania major (24). In the case of adenovirus, human im-
FIG. 5. A single mutation in the VEE E2 glycoprotein gene prevents infection in vivo of DC, while a second-site suppressor mutation restores the ability of VEE
to infect DC. Sections of the draining lymph node 12 h following s.c. inoculation in the rear footpad with 103 IU of either GFP-VRP-V3010 (magnification, 3600) (a),
GFP-VRP-V3533 (magnification, 3400) (b), or HA-VRP-V3533 (c to f). HA-GFP-V3533 sections were doubly immunostained with Ab specific for influenza virus and
FcgIII/IIR and analyzed by confocal microscopy (magnification, 3600) (c and d) or for influenza virus and CR-1 (e and f) and analyzed by fluorescence microscopy
(magnification, 3600) (e and f).
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munodeficiency virus, and L. major, cell types other than DC
represent additional significant targets of infection. In LCMV,
however, a mutation introduced into the Armstrong strain
(clone 13) shifts cell tropism from macrophages primarily to
DC in the spleen.
Pathogen infection of DC, as described in several systems,
can promote potent antipathogen immunity due to efficient
antigen presentation and/or immunosuppression due to im-
pairment or depletion of infected DC (2). Persistent L. major
infection of DC is correlated with healing of lesions, lifelong
immunity, and resistance to reinfection (24), whereas the shift
in cell tropism in the LCMV clone 13 results in a broad im-
munosuppression due to the depletion of infected DC (3).
Measles virus infection of DC in vitro results in a loss of
antigen-presenting capacity and has been proposed as a major
cause of the transient immunosuppression seen following mea-
sles virus infections in vivo (2, 20). As with L. major, VEE
infection in mice or humans is not associated with immuno-
suppression. Virulent and attenuated clones of VEE, as well as
VEE vaccine vectors expressing specific antigens, are strongly
immunogenic (4, 5, 10, 21, 27).
Time course studies of the disappearance of infected cells in
the footpad and the appearance of infected cells in the lymph
node suggest that VEE-infected Langerhans cells in the skin
rapidly migrate to the draining lymph node, where they seed
the infection of other DC. A similar series of steps has been
described for L. major, where infected Langerhans cells from
the skin traffic parasites to the draining lymph node (25). The
studies reported here, however, cannot distinguish between
Langerhans cells becoming infected in the skin and migrating
to the lymph node and the possibility that Langerhans cells
constantly circulate to the node and become infected by free
virus carried by the lymph. Recent studies indicate a size re-
striction of particle movement into the paracortex of the lymph
node, with large molecules and particles the size of VEE being
shunted directly to areas proximal to high endothelial venules
(17). VEE infection of Langerhans cells may provide a critical
mechanism providing access of the virus to the region of the
lymph node where subsequent rounds of infection occur. In
addition, it is possible that migration of infected DC plays an
important role in trafficking the virus to other lymphoid tissues.
Results of studies with the mutated V3010 and its cloned
revertant, V3533, further illustrate the importance of Langer-
hans cells in the spread of VEE. The mutation in V3010 ab-
rogated the appearance of infected Langerhans cells in the
draining lymph node, whereas the suppressor mutation in
V3533 restored the ability of virus to infect DC in vivo. These
results are strongly correlated with the loss (V3010) and sub-
sequent recovery (V3533) of viral spread and partial virulence.
In addition, these mutations identify the E2 glycoprotein as a
primary determinant of VEE cell tropism in vivo. Because the
replicon genomes of VRP lack the glycoprotein genes, it is
highly likely that the mutations exact their targeting effects at
the level of viral spread, attachment to a target cell, penetra-
tion, and/or uncoating.
In summary, the results of these experiments reveal several
new aspects of VEE pathogenesis. First, the initial site of virus
replication is not at the site of inoculation but, rather, in the
lymph node draining the inoculation site. Second, the initial
cells infected by VEE are Langerhans cells, either in the lymph
node or, more likely, at the site of the inoculation, from where
they migrate rapidly to the draining lymph node. Finally, the
specificity of this process is controlled by the VEE E2 glycop-
rotein, since it functions in early interactions with target cells in
vivo. These observations were made possible by the genetic
manipulation of VEE to yield wild-type and mutant virions
capable of only a single cycle of replication, thus unequivocally
identifying the earliest pathogenic events following inocula-
tion.
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